(+/-)-9-Hydroxyoctadec-12-ensaeure | 13017-32-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (+/-)-9-Hydroxyoctadec-12-ensaeure
• 英文别名: 9-Hydroxy-cis-12-octadecensaeure；9-Hydroxy-12-octadecenoic acid；(E)-9-hydroxyoctadec-12-enoic acid
• CAS: 13017-32-8；26806-10-0；35017-84-6；38231-95-7；73891-08-4；105182-18-1
• 化学式: C₁₈H₃₄O₃
• 分子量: 298.466
• InChiKey: BNZYDQIAPCVNAT-SOFGYWHQSA-N

物化性质

• 沸点：
  445.5±28.0 °C(Predicted)
• 密度：
  0.957±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  21
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
  申请人：ARIYA THERAPEUTICS INC

  公开号：WO2019046491A1

  公开（公告）日：2019-03-07

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其制药组合物，制备这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所提供的脂质前药或其制药组合物。
• [EN] LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES DE PRÉGNANE ET LEURS UTILISATIONS
  申请人：PURETECH HEALTH LLC

  公开号：WO2020028787A1

  公开（公告）日：2020-02-06

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，以及其制药组合物、生产这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所述的脂质前药或其制药组合物。
• [EN] LIPID PRODRUGS OF NEUROSTEROIDS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES
  申请人：PURETECH LYT INC

  公开号：WO2021159021A1

  公开（公告）日：2021-08-12

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统导向的脂质前药、其药物组合物、制备此类前药和组合物的方法，以及提高包含在脂质前药中的治疗剂的生物利用度或其他特性的方法。本发明还提供了治疗如本文所述的疾病、紊乱或状况的方法，包括向有需要的患者施用所述的脂质前药或其药物组合物。
• [EN] LIPID PRODRUGS OF CELECOXIB AND USES THEREOF<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE CÉLÉCOXIB ET LEURS UTILISATIONS
  申请人：UNIV MONASH

  公开号：WO2021051172A1

  公开（公告）日：2021-03-25

  The present invention provides methods of treating metabolic diseases including obesity, insulin resistance and type 2 diabetes with inhibitors of COX-2 or VEGFR and lipid prodrugs of COX-2 inhibitors, in particular celecoxib lipid prodrugs, that promote transport of the pharmaceutical agent to the lymphatic system and which enhance release of the parent agent.

  本发明提供了一种治疗代谢性疾病，包括肥胖、胰岛素抵抗和2型糖尿病的方法，使用COX-2或VEGFR的抑制剂以及COX-2抑制剂的脂质前药，特别是促进药物剂运送到淋巴系统并增强母药释放的Celecoxib脂质前药。
• Fluorine-containing compounds
  申请人：MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD.

  公开号：EP0473871A2

  公开（公告）日：1992-03-11

  A fluorine-containing compound represented by the general formula [I]: wherein Rf is a fluoroalkyl ether end group having 5 to 50 carbon atoms, R1 is an aliphatic alkyl end group or an aliphatic alkenyl end group, R2 is an aliphatic alkylene group or an aliphatic polyalkylene oxide group which have no or one or more carbon atoms, each of R3 and R4 is an aliphatic alkylene group having no or one or more carbon atoms, X is a connecting group selected from the group consisting of (wherein R5 is an aliphatic alkylene group having no or one or more carbon atoms, and R6 is a hydrogen atom or an aliphatic alkyl group having 1 to 12 carbon atoms), each of W and Y is connecting group selected from the group consisting of (wherein R7 is a hydrogen atom or a methyl group), Z is a connecting group selected from the group consisting of and each of 1, m and n is zero or 1. There are disclosed a fluorine-containing compound of a specific structure which has in the molecule a fluoroalkyl ether end group, an aliphatic hydrocarbon end group and a carboxyl end group, and has a molecular weight of hundreds to about 3,000; and a process for producing the fluorine-containing compound. This fluorine-containing compound can be utilized in magnetic recording media in the form of a lubricant composition.

  由通式[I]表示的含氟化合物： 其中 Rf 是具有 5 至 50 个碳原子的氟烷基醚端基，R1 是脂肪族烷基端基或脂肪族烯基端基，R2 是不含碳原子或含一个或多个碳原子的脂肪族亚烷基或脂肪族聚氧化烯基，R3 和 R4 各是不含碳原子或含一个或多个碳原子的脂肪族亚烷基，X 是选自下列组的连接基团： R5 是不含碳原子或含一个或多个碳原子的脂肪族亚烷基，R6 是氢原子或脂肪族聚氧化烯基，R7 是不含碳原子或含一个或多个碳原子的脂肪族聚氧化烯基，R8 是不含碳原子或含一个或多个碳原子的脂肪族聚氧化烯基。 (其中 R5 为无碳原子或有一个或多个碳原子的脂族亚烷基，R6 为氢原子或有 1 至 12 个碳原子的脂族烷基），W 和 Y 各为选自以下组的连接基团 (其中 R7 是氢原子或甲基），Z 是选自以下组别的连接基团 1、m 和 n 中的每一个均为 0 或 1。本发明公开了一种具有特定结构的含氟化合物，其分子中具有氟烷基醚端基、脂肪族烃端基和羧基端基，分子量在数百至约 3,000 之间；还公开了一种生产该含氟化合物的工艺。这种含氟化合物可以润滑剂组合物的形式用于磁记录介质中。